Skip to main content

Advertisement

Figure 8 | EJNMMI Research

Figure 8

From: Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood–brain barriers studied with (R)-[11C]verapamil positron emission tomography

Figure 8

Brain-to-plasma partition coefficients (A-D) and transport clearances across the BBB (E-H). (A) V T-NLME in rats at baseline, (B) V T-NLME in rats during and after tariquidar administration, (C) V T-NLME in rats in post-inhibition scan, and (D) V T-NLME in WB in humans at baseline (V T), during and after tariquidar administration (V T (2 mg/kg)) and in post-inhibition scan (V* T(2 mg/kg)). (E) Q in and Q out in rats at baseline, (F) Q out in rats during and after tariquidar administration (3 or 15 mg/kg), (G) Q out in rats in post-inhibition scan, and (H) Q in, Q out at baseline, Q out during and after tariquidar administration (2 mg/kg), and Q* out in post-inhibition scan (2 mg/kg) in humans. *p < 0.05, **p < 0.01, ***p < 0.001; not significant p > 0.05.

Back to article page